Gene Therapy Effective Treatment Against Gum Disease Dec 14, 2008
Co-authors included Haim Burstein, a research scientist at Targeted Genetics Corporation, and members of U-M research team Joni Cirelli, Chan Ho Park, Jim Sugai and Katie MacKool. Adapted from materials provided by , via , a service of AAAS. Email or share this story. (Science Daily)
Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology Jun 12, 2008
SEATTLE and PARIS, June 12 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (Nasdaq: ) announced today that positive results of a Phase 1/2 clinical study demonstrate that tgAAC94, its investigational agent designed to inhibit activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation, is well tolerated and may improve disease symptoms in inflammatory arthritis patients refractory to other therapies, including systemic TNF antagonists ... About Targeted Genetics... (PR Newswire)
Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings May 31, 2008
Trial Demonstrates Safety and Preliminary Efficacy and Supports Further Clinical Development of tgAAC94 BOSTON and SEATTLE, May 30 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (Nasdaq: ) issued a news release earlier today, entitled "Targeted Genetics Reports Additional Data From Inflammatory Arthritis Clinical Trial," announcing additional interim data from its Phase 1/2 clinical study of tgAAC94 in patients with inflammatory arthritis ... About Targeted Genetics Corporation Targeted... (PR Newswire)
Effect of Gene Therapy on Visual Function in Leber’s Congenital Amaurosis May 22, 2008
From the Institute of Ophthalmology, University College London (J.W.B.B., A.J.S., S.S. Barker, S.R., R.H., K.B., A.V., G.E.H., A.S., S.S. Bhattacharya, F.W.F., G.S.R., A.T.M., R.R.A.); Moorfields Eye Hospital (J.W.B.B., A.V., G.E.H., A.T.M.); the National Institute of Health Research Biomedical Research Centre for Ophthalmology, University College London and Moorfields Eye Hospital (J.W.B.B., G.S.R., A.T.M., R.R.A.); the Department of Civil and Environmental Engineering, University College... (New England Journal of Medicine)
Arthritis Gene Therapy Trial Resumes After Patient Death Investigated Nov 28, 2007
Targeted Genetics Corporation said the action followed the agency's review of the trial's safety data on 127 participants and that surrounding "a fatal serious adverse event" in particular ... In a statement released on 26th July this year, the FDA said that following a report from Targeted Genetics Corporation of Seattle on 24th July, about the death of a patient who received "an investigational gene therapy product in a clinical trial", even though the causes were unknown, it placed the trial... (Medical News Today)
Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis Sep 18, 2007
SEATTLE, Sept. 17 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (Nasdaq: ) today reported on the public hearing conducted by the National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC), which reviewed the serious adverse event reported by Targeted Genetics surrounding the death of a patient participating in the Company's Phase I/II trial of tgAAC94 for inflammatory arthritis ... About Targeted Genetics Targeted Genetics Corporation is a biotechnology company... (PR Newswire)
Gene therapy death raises ethical issues Sep 14, 2007
Later this month, a committee of the National Institutes of Health will discuss the recent death of 36-year-old Illinois resident Jolee Mohr in an experimental gene therapy study sponsored by Targeted Genetics Corporation. The NIH committee is an advisory body only, but its meeting may provide Mohr's family - and the rest of us - a rare glimpse into the inner workings of the clinical trial enterprise in the United States. (San Francisco Chronicle -- Opinion)
Targeted Genetics Reports Interim Phase II Data From HIV/AIDS ... Aug 22, 2007
Targeted Genetics Corporation (NASDAQ: TGEN) presented interim data this week from a Phase II trial of tgAAC09 in Africa ... Targeted Genetics Corporation is a biotechnology company committed to the development of innovative, targeted molecular therapies for the prevention and treatment of acquired and inherited diseases with significant unmet medical need ... Investor and Media Contact: Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392. (CNNMoney.com)
Gene Therapy Trial Halted While Woman's Death Investigated Aug 14, 2007
Jolee Mohr who was 36 years old, died at the University of Chicago Medical Center on 24th July, 22 days after having a second injection of the experimental drug tgAAC94, made by Targeted Genetics Corporation. As a precautionary measure, the trial has stopped while an investigation is conducted into the cause of Jolee Mohr's death. (Medical News Today)
FDA Statement On Gene Therapy Clinical Trial Jul 31, 2007
On July 24, 2007 the U.S. Food and Drug Administration (FDA) was informed by Targeted Genetics Corporation of Seattle about the death of a patient who received an investigational gene therapy product in a clinical trial for the treatment of active inflammatory arthritis. FDA's condolences go to the patient's family. (Science Daily)
Phase I clinical trials of AIDS vaccine end Feb 24, 2007
The vaccine candidate was developed by a Pune researcher Dr Pervin Anklesaria at the Seattle-based Targeted Genetics Corporation, a biotechnology company developing gene therapy products for the treatment of acquired and inherited diseases, and Columbus Children's Research Institute in partnership with IAVI (International Aids Vaccine Initiative). "The conduct of the vaccine trial went smoothly. No safety concerns were identified and the vaccine was well tolerated," Sanjay Mehendale,... (Times of India)
